» Articles » PMID: 16036240

Determinants of HAART Discontinuation Among Injection Drug Users

Overview
Journal AIDS Care
Publisher Informa Healthcare
Date 2005 Jul 23
PMID 16036240
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to identify psychosocial determinants of, and self-reported reasons for, HAART discontinuation among HIV-positive injection drug users (IDUs). We examined correlates between sociodemographic characteristics, drug use and risk behaviors, outcome expectations, adherence self-efficacy, social support and HAART discontinuation among 160 HIV-positive participants in the Vancouver Injection Drug Users' Study (VIDUS). Logistic regression was used to identify the factors independently associated with discontinuation of HAART. Seventy-one (44%) study participants discontinued HAART during the study period. Factors independently associated with discontinuation of HAART included recent incarceration (OR = 4.84, p = 0.022), negative outcome expectations (OR = 1.41, p = 0.001), adherence efficacy expectations (OR = 0.70, p = 0.003) and self-regulatory efficacy (OR = 0.86, p = 0.050). The most frequently cited reasons provided for discontinuing HAART were being in jail (44%) and medication side effects (41%). The results of this study suggest that psychological constructs derived from self-efficacy theory are highly germane to the understanding of HAART discontinuation behavior and interventions that may change it. Incarceration may result in interruptions in HAART among IDUs, and programmatic changes may be needed to promote optimal retention on HAART among incarcerated HIV-infected IDUs.

Citing Articles

Diagnosis, Treatment, and Prevention of HIV Infection among Detainees: A Review of the Literature.

Russotto Y, Micali C, Lagana N, Marino A, Campanella E, Celesia B Healthcare (Basel). 2022; 10(12).

PMID: 36553904 PMC: 9777892. DOI: 10.3390/healthcare10122380.


A review of HIV-specific patient-reported measures of perceived barriers to antiretroviral therapy adherence: what themes are they covering?.

Engler K, Toupin I, Vicente S, Ahmed S, Lebouche B J Patient Rep Outcomes. 2019; 3(1):37.

PMID: 31250222 PMC: 6597666. DOI: 10.1186/s41687-019-0124-3.


Prevalence and Correlates of Reporting Difficulty Taking Antiretroviral Treatment Among HIV-Positive Illicit Drug Users in Vancouver, Canada: A Longitudinal Analysis.

Yeung B, Mohd Salleh N, Socias E, Dong H, Shoveller J, Montaner J AIDS Behav. 2018; 23(5):1250-1257.

PMID: 30284081 PMC: 7098176. DOI: 10.1007/s10461-018-2271-6.


Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence.

Nafradi L, Nakamoto K, Schulz P PLoS One. 2017; 12(10):e0186458.

PMID: 29040335 PMC: 5645121. DOI: 10.1371/journal.pone.0186458.


Community mapping of sex work criminalization and violence: impacts on HIV treatment interruptions among marginalized women living with HIV in Vancouver, Canada.

Goldenberg S, Deering K, Amram O, Guillemi S, Nguyen P, Montaner J Int J STD AIDS. 2017; 28(10):1001-1009.

PMID: 28056726 PMC: 5494020. DOI: 10.1177/0956462416685683.